WO2000078917A1 - Dispositif et procede d'analyse d'un echantillon biologique - Google Patents

Dispositif et procede d'analyse d'un echantillon biologique Download PDF

Info

Publication number
WO2000078917A1
WO2000078917A1 PCT/US2000/013056 US0013056W WO0078917A1 WO 2000078917 A1 WO2000078917 A1 WO 2000078917A1 US 0013056 W US0013056 W US 0013056W WO 0078917 A1 WO0078917 A1 WO 0078917A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluid
sample
particles
chamber
microspheres
Prior art date
Application number
PCT/US2000/013056
Other languages
English (en)
Inventor
Peter Lea
Original Assignee
Umedik, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/335,732 external-priority patent/US6403384B1/en
Priority claimed from PCT/CA1999/001079 external-priority patent/WO2000029847A2/fr
Application filed by Umedik, Inc. filed Critical Umedik, Inc.
Priority to AU47126/00A priority Critical patent/AU4712600A/en
Publication of WO2000078917A1 publication Critical patent/WO2000078917A1/fr
Priority to US09/866,305 priority patent/US20020019062A1/en
Priority to US11/319,117 priority patent/US20060105469A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502753—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/02—Adapting objects or devices to another
    • B01L2200/025—Align devices or objects to ensure defined positions relative to each other
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/04—Closures and closing means
    • B01L2300/041—Connecting closures to device or container
    • B01L2300/045—Connecting closures to device or container whereby the whole cover is slidable
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0609—Holders integrated in container to position an object
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0681—Filter
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0825—Test strips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/16—Surface properties and coatings
    • B01L2300/168—Specific optical properties, e.g. reflective coatings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces

Definitions

  • This invention relates to a device for separating a fluid component, such as plasma, from a non- fluid component of a biologic sample, such as blood, using suitable small particles such as microspheres.
  • a fluid component such as plasma
  • a non- fluid component of a biologic sample such as blood
  • suitable small particles such as microspheres.
  • This invention also relates to a device and
  • the invention further relates to a quantitative assay method and device for measuring one or more analytes in a biologic fluid sample using a point-of-care assay method and device.
  • the sample could be a suspension or solution which is prepared for the purpose of testing for the presence and, optionally, the amount of one or more micro-organisms.
  • the sample could be a suspension or solution which is prepared for the purpose of testing for the presence and, optionally, the amount of one or more proteins.
  • the proteins could be, for example, an antibody or an antigen.
  • the test results can be analyzed using a suitable analyzer and, optionally, the assay test results are transmitted by way of digital transmission systems to permit further evaluation of the data. The data generated in this manner may be used to create databases suitable for diagnostic or prognostic purposes.
  • a common assay is the pregnancy test device, which involves contacting a urine sample with a test pad, comprising a bibulous chromatographic strip containing reagents capable of reacting with and/or binding to of human chorionic gonadotropin (HCG).
  • HCG human chorionic gonadotropin
  • Nonbibulous lateral flow refers to liquid flow in which all of the dissolved or dispersed components of a liquid, which are not permanently entrapped or filtered out, are carried at substantially equal rates and with relatively unimpaired flow laterally through a stabilized membrane. This is distinguished from preferential retention of one or more components as would occur, for example, in materials capable of absorbing or imbibing one or more components, as occurs in chromatographic configurations.
  • a sample (which may contain the analyte of interest) is collected on the “sample receiving zone” from which it flows to the “labelling zone” at which point it encounters a specific binding reagent for the analyte coupled to visible moieties (the "assay label"), then flows to a “capture zone” where the analyte bound to visible moieties is captured.
  • U.S. Patent 5,300,779 issued April 5, 1994 entitled “Capillary Flow Device” describes methods and devices for measuring an analyte in a sample mixed with reagents, the devices defining a flow path.
  • the specific binding by agglutination may provide for changes in flow rate, light patterns of a flowing medium, or light absorption or scattering which permit measurement of the analyte of interest.
  • U.S. Patent 5,110,724 issued May 5, 1992, entitled “Multi-Analyte Device” the invention described is an assay device for assaying multiple analytes in a drop- sized blood sample.
  • a dispenser distributes a small volume blood sample to multiple transfer sites by capillary flow of the blood sample through sieving and distributing matrices which separate blood cells from plasma as the sample fluid migrates toward the transfer sites.
  • a test plate in the device carries multiple absorbent pads, each containing reagent components for use in detection of a selected analyte. The test plate is mounted on the dispenser toward and away from a transfer position at which the exposed surface regions of the pads are in contact with associated sample-transfer sites, for simultaneous transfer of sample fluid from such sites to the pads in the support.
  • the similar invention is described and the glass fibre filters are prepared from fibers with diameters between 0.10 and 7.0 ⁇ m.
  • the sample which may contain the analyte (a), (the substance being tested for) is mixed with (b) an antibody which binds to the substance being tested for, which antibody is immobilized on a solid support, and (c) another antibody for the substance being tested for which is conjugated to a detectable marker, to thereby form a complex between (b), the substance being tested for and (c) and causes the marker to be immobilized and detected.
  • the described invention is a method and apparatus for conducting specific binding pair assays, such as immunoassays
  • the test substrate is a porous membrane on which a member of the binding pair is affixed in an "indicator zone".
  • the sample is applied and is permitted to flow laterally through the indicator zone and any analyte in the sample is complexed with the affixed specific binding member, and detected.
  • a novel method of detection employs entrapment of observable particle in the complex, for instance, red blood cells of blood can be used as the observable particles for detection of the complex.
  • a serious deficiency in current one-step assays for the measurement and/or detection of an analyte is that they provide only qualitative results rather than quantitative results. That is to say that the presence or absence of the analyte may be determined but the actual amount or concentration of analyte present in the sample would still not be known.
  • the assay of the present invention provides quantitative results as the test is performed in a determinable volume. In the prior art methods it is not possible to consistently identify the exact volume of the test sample in repeated testings since the fluids must wash through the test strips.
  • prior art methods using chromatographic strips and fiberglass strips require larger initial volumes of the biologic fluid in order to mobilize the proteins and labels in the strips. This is particularly true when the biologic fluid is blood and the plasma must first be separated from the blood sample.
  • An advantage of the device and method of the present application is that very small fluid samples can be used to measure one or more analytes.
  • the assay method and device of the present invention is also advantageous because the test volume can be made constant and therefore repeated testings will yield quantitative data which can be directly compared between samples and within a sample. It is an advantage of the present invention that the assay device and methodology allows for separation of the fluid component, such as plasma from the non- fluid component of a sample, such as whole blood, during the assaying of the fluid sample.
  • the device and assay methodology of the present invention a generic point-of-care platform suitable for use in one or more diagnostic or prognostic assays performed on one or more fluid samples.
  • a method for separating out the fluid component of a biologic sample is provided.
  • the biologic sample is placed in contact with a group of microspheres and the fluid component separates from the sample as the fluid portion flows through the microspheres, by capillary action.
  • the microspheres are of a defined diameter or size.
  • particles of non-uniform size and/or shape may be used to separate a fluid portion from a biologic sample instead of using microspheres.
  • a quantitative assay method and device are provided for measuring one or more analytes in a fluid sample using a point-of-care assay method and device.
  • the assay and device are designed for use by a patient, at the bedside of a patient, or in a doctor's office.
  • the test results are analyzed using a suitable analyzer and, optionally, the assay test results are transmitted by way of digital transmission systems to permit further evaluation of the data by an off-site professional.
  • the microspheres, or other particles act as a dynamic filter to extract or partition a fluid portion away from the non-fluid portion.
  • the channels and the contacts between the particles may be transient since the beads exhibit motion during the separation step. Therefore the rapid, instantaneous capillary extraction is by a dynamic capillary filter created by the transient capillary channels formed by the interstitial spaces between the microspheres or particles.
  • an assay method and assay device are provided for testing small volumes of fluid samples, such as biologic fluids, including blood, in a timely manner.
  • the assay device is preferably a portable assay device.
  • a method and device are provided for testing biologic fluid samples in which a consistent volume of the biologic fluid sample is tested for one or more analytes and the data generated from the tests are used for collecting and compiling in a database pertaining, for example, to a particular disease condition.
  • the data collected can be used to train neural network algorithms and the algorithms may then be used to provide diagnostic and/or prognostic information based on the individual test results of any given test subject.
  • the cellular components of a blood sample are separated from plasma by allowing the whole blood to be exposed to microsphere beads which permit the plasma, but not the cellular component, to pass in the spaces formed between the microspheres by capillary action.
  • the present invention is not limited to the separation of cells from plasma in blood but includes broader applications where microsphere beads may be used to separate a fluid component from a cellular component in a biologic fluid.
  • the microsphere beads are effectively acting as a fluid filter.
  • a device is provided for separating plasma from blood in a sample.
  • the device comprises a plurality of microspheres disposed in a transiently abutting relation and forming therebetween a plurality of capillary channels, whereby when the microspheres are disposed in fluid communication with a blood sample cellular and plasma components of the biologic sample are separated by capillary flow of the plasma component through the capillary channels formed by the interstitial spacing between abutting microspheres.
  • the device comprises a plurality of groups of smaller microspheres each impregnated with a different label and interspersed with the larger microspheres in separate zones of the larger microspheres.
  • the microspheres may be of substantially the same diameter, or the microspheres may be of differing diameters.
  • the size of microsphere selected may be based on the viscosity of the sample or the size of the component one wishes to exclude or separate.
  • the microspheres are bundled in a fluid-permeable material or the microspheres are maintained in a transiently abutting relation by a surface tension of the fluid which passes through them, for example plasma.
  • the microsphere beads also known simply as microspheres, are dried on a surface of the device.
  • the device comprises a sample shelf adjacent to the fluid entrance and the microspheres are disposed on the sample shelf.
  • the device comprises a sample well disposed adjacent to the fluid entrance which is capable of holding the microsphere beads in place, and which also acts to ensure that no sample bypasses the microsphere beads.
  • the device comprises a plurality of smaller microspheres which are impregnated with at least one label interspersed with a plurality of larger microspheres such that the smaller microspheres occupy the interstitial spacing between the larger microspheres and release a label into the fluid as it flows through the interstitial spacing between the larger microspheres.
  • microspheres there may be a plurality of groups of smaller microspheres each impregnated with a different label and interspersed with the larger microspheres in separate zones of the larger microspheres.
  • the smaller microspheres may be mobilized and carried forward by the fluid as it passes along the capillary channels formed by the larger microspheres.
  • the device comprises an indicator means containing identification information to be associated with results of the assay (e.g., patient information), for example a bar code which can be read by a bar code reader.
  • a method of separating fluid from a biologic sample is provided.
  • the sample has a fluid component and a non-fluid component and the method comprises the steps of,
  • a method of assaying a fluid sample which utilizes a device comprising a capillary chamber defined by first and second opposed surfaces spaced a capillary distance apart having a fluid entrance and at least one reagent disposed within the capillary chamber, comprising the steps of,
  • the method further comprise the step of analyzing the reagent to determine a proportion of the reagent which binds to the sample.
  • the method further comprises a plurality of capillary chambers for conducting a plurality of assays on one or more fluid samples.
  • the results of the tests are recorded in a computer database and may be further applied in a trained neural network algorithm to generate a profile of one or more selected disorders.
  • the assay further comprises the step of applying a receiver operating characteristic analysis to the data to determine a statistical significance of the data.
  • a wick or a capillary is brought into fluid communication with the fluid sample to remove the fluid sample from the capillary chamber.
  • microspheres are used to separate a cellular component from a fluid component in a biologic fluid, for example plasma from whole blood, and the resulting fluid component can be tested in conventional chromatography test strips.
  • a biologic fluid for example plasma from whole blood
  • the microsphere beads of the present invention may be used as a labeling device, in addition to a filtration device, in standard nitrocellulose chromatography assays.
  • microspheres are used to separate and/or concentrate microbial contaminants from a suspension of a sample to detect the presence of and quantify the numbers of microbial contaminants in the sample.
  • samples may include, for example, food, water, soil or fecal samples.
  • a device for assaying a fluid sample comprises a chamber defined by two non-contiguous surfaces and having at least one fluid entrance.
  • a biochip The non-contiguous surfaces of the biochip are separated by a distance sufficient to create capillary flow of the fluid sample into the chamber through the fluid entrance.
  • the biochip further includes a dynamic capillary filter which is in fluid communication with the fluid entrance and which also includes a plurality of particles.
  • the particles are in a transiently abutting relation with one another and form interstitial spaces therebetween, whereby when the fluid sample contacts the dynamic capillary filter, the fluid sample flows into the dynamic capillary filter, whereupon a fluid component of the fluid sample is separated from a non-fluid component of the fluid sample by passage through the interstitial spaces of the dynamic capillary filter and the fluid component thereafter flows into the chamber through the fluid entrance.
  • the biochip further includes one or more reagents.
  • An analyzer capable of detecting a reaction between the reagent and at least one analyte that may be present in the fluid sample is provided to constitute an assaying system with the biochip.
  • the biochip includes a chamber defined by two non-contiguous surfaces and having at least one fluid entrance. The non-contiguous surfaces are separated by a distance sufficient to create capillary flow of the fluid sample into the chamber through the fluid entrance.
  • the device further includes a dynamic capillary filter which is in fluid communication with the fluid entrance and which also includes a plurality of particles.
  • the particles are in a transiently abutting relation with one another and form interstitial spaces therebetween, whereby when the fluid sample contacts the dynamic capillary filter, the fluid sample flows into the dynamic capillary filter, whereupon a fluid component of the fluid sample is separated from a non- fluid component of the fluid sample by passage through the interstitial spaces of the dynamic capillary filter and the fluid component thereafter flows into the chamber through the fluid entrance.
  • One or more reagents can be bound to an interior face of at least one of the non-contiguous surfaces.
  • the reagent is capable of reacting with one or more analytes that may be present in the fluid sample.
  • the assaying system further contains an analyzer capable of detecting a reaction between the reagent and at least one of the one or more analytes that may be present in the fluid sample.
  • a method for detecting or measuring the amount of a component of a fluid sample comprises the steps of: a) providing an assay device that includes a biochip, which includes a chamber defined by two non-contiguous surfaces and having at least one fluid entrance. The non-contiguous surfaces are separated by a distance sufficient to create capillary flow of the fluid sample into the chamber through the fluid entrance.
  • the device further includes a dynamic capillary filter which is in fluid communication with the fluid entrance and which also includes a plurality of particles.
  • the particles are in a transiently abutting relation with one another and form interstitial spaces therebetween, whereby when the fluid sample contacts the dynamic capillary filter, the fluid sample flows into the dynamic capillary filter, whereupon a fluid component of the fluid sample is separated from a non-fluid component of the fluid sample by passage through the interstitial spaces of the dynamic capillary filter and the fluid component thereafter flows into the chamber through the fluid entrance.
  • the biochip may further include one or more reagents bound to an interior face of at least one of the non-contiguous surfaces. The reagent is capable of reacting with one or more analytes that may be present in the fluid sample.
  • the assay device further contains the analyzer capable of detecting a reaction between the reagent and at least one of the one or more analytes that may be present in the fluid sample; b) applying the fluid sample to the assay device under conditions under which the fluid sample passes through the dynamic capillary filter and thereafter into the chamber through the fluid entrance; c) detecting a presence of a reaction product formed as a result of a reaction between the reagent and one or more analytes that may be present in the fluid sample; and d) optionally, measuring at least one of an amount of and a concentration of the reaction products.
  • a method for assessing pre-and post symptomatic health conditions of a patient comprising the steps of: a) obtaining a bodily sample from the patient; b) analyzing the bodily sample for the presence, absence, and optionally a concentration or amount of an analyte; c) repeating steps a) and b) a desired number of times, the desired number being at least once, to create a data pool for the patient; d) constructing a database, based on the patient's medical history, current
  • microspheres could be replaced by non- uniform particles of differing sizes and/or shapes as described further below.
  • silica sand could be used to replace the polystyrene microsphere beads.
  • suitable particles would be known to a person skilled in the art having the benefit of the present description.
  • Figure 1 is an schematic, exploded, perspective view of an embodiment of the device of the present invention.
  • Figure 2 is a longitudinal cross section of the preferred embodiment illustrated in Figure 1 along line 1A - 1 A.
  • Figure 2A is an end elevation view of the device illustrated in Figure 2 taken from the perspective of line 2 A - 2 A.
  • Figure 3 is a side view of an embodiment described in Example 1 illustrating the cover slip in relation to the beads when starting to form the curl.
  • Figure 4 is also a side view of an embodiment described in Example 1 illustrating the curl after formation
  • Figure 5 is another side view of an embodiment described in Example 1 illustrating the position of the cover slip in relationship to the beads on the microscope slide.
  • Figure 6 is a top plan view of an embodiment described in Example 1.
  • Figure 7 is a side view of an embodiment described in Example 2 illustrating the label pad variant.
  • Figure 7A is a side view of another embodiment described in Example 2 illustrating the replacement of the label pad with microsphere beads.
  • Figure 8 illustrates an example ROC curve for the expected test results for a neural network risk analysis test.
  • Figure 9 is a photomicrograph taken at 400x magnification using a light powered microscope showing the appearance of unseparated yogurt as applied to the shelf of the biochip.
  • Figure 10 is a photomicrograph taken at 400x magnification using a light powered microscope showing a fluid portion of the yogurt seen in Figure 9 after
  • Figure 11 is a photomicrograph taken at 400x magnification using a light powered microscope showing a fluid portion of the yogurt seen in Figure 9 after
  • microsphere beads having a 10 ⁇ m diameter.
  • Figure 12 is a photomicrograph taken at 400x magnification using a light powered microscope showing the appearance of unseparated E.coli and bread suspension as applied to the shelf of the biochip.
  • Figure 13 is a photomicrograph taken at 400x magnification using a light powered microscope showing a fluid portion of the E.coli/bread suspension seen in
  • Figure 14 is a photomicrograph taken at 400x magnification using a light powered microscope showing the appearance of unseparated cow feces as applied to the shelf of the biochip.
  • Figure 15 is a photomicrograph taken at 400x magnification using a light powered microscope showing a fluid portion of the cow feces seen in Figure 14 after separation using microsphere beads having 15 micrometer diameters.
  • Figure 16 is a photomicrograph taken at 400x magnification using a light powered microscope showing a fluid portion of the cow feces seen in Figure 14 after
  • microsphere beads having a 10 ⁇ m diameter.
  • Figure 17 is a photomicrograph taken using a light powered microscope showing silica sand as applied to the shelf of the biochip and showing a 1 mm scale illustrating the size of the silica sand grains.
  • Figure 18 is a photomicrograph taken at 400x magnification using a light powered microscope showing a fluid portion of the E.coli/b ⁇ ead suspension seen in Figure 12 after separation using silica sand grains.
  • Figure 19 is a photomicrograph taken at 400x magnification using a light powered microscope showing a fluid portion of the cow feces suspension seen in Figure 14 after separation using silica sand grains.
  • Figure 20A is a perspective view of the top portion of another embodiment of the device of the present invention, showing a well in which the microsphere beads may be placed.
  • Figure 20B is a is a perspective view of the bottom portion of another embodiment of the device of the present invention, showing tracks in which a cap may be slidably placed.
  • Figure 21 is a perspective view of a cap that fits slidably over the device of
  • the present invention relates to a method of separating a fluid component from a biologic sample using microsphere beads or other suitable particles.
  • the present invention further relates to a device and a method for analyzing the presence or absence of an analyte in a biologic fluid sample.
  • the invention also relates in one aspect to quantifying with precision the amount of one or more analytes present in a biologic fluid sample.
  • the present invention can also provide quantitative as well as qualitative results.
  • the present invention further relates to a method for interpreting test results obtained by the methods of the present invention and can be used to further identify certain medical conditions from which a person or animal may be suffering or is likely to suffer from in the future.
  • the present invention further relates to a prognostic assay technique in which the results of the test assay defined in the present invention may be used to predict the likelihood of a person or animal developing a certain condition or disease state at a future time.
  • fluid sample as used in this specification, is intended to be interpreted broadly to include suspensions and other samples that have a fluid portion which can be separated by fluid flow and/or capillary action.
  • suspensions of food, water, soil, or fecal matter could be tested for the presence of microbial, i.e., viral, bacterial, or fungal, contaminants.
  • the fluid component containing an analyte of interest may be used to measure any of the following, alone or in combination: a)the presence of the analyte in the sample; b)the absence of the analyte in the sample; c)concentration of the analyte in the sample; or d)total amount of analyte in the sample.
  • Suitable analytes which may be measured by the assay and device of the present invention include soluble analytes; i.e., enzymes, proteins, bacteria, fungi, viruses, antigens, antibodies, immunoglobulins, drugs, and hormones. Other suitable analytes would be known to one skilled in the art.
  • the assay and device of the present invention are also useful for the detection and measurement of drugs of abuse in human biologic samples, such as performance enhancing drugs or street drugs.
  • Some biologic samples can be assayed without first separating out cellular components; however, in many cases, it is necessary to first separate the fluid component from any cellular components.
  • the cellular component can interfere with the assay. Therefore, the plasma must be separated from the cellular components so that the cellular components of the blood do not interfere with the testing for the analyte which is present in the plasma.
  • the fluid component of a biologic sample can be separated from its non- fluid component by applying the sample to a group of particles, such as microsphere beads.
  • a group of particles such as microsphere beads.
  • the fluid component flows in between the particles as they move, forming transient channels or pores.
  • the beads act as a means of separating the fluid component from the non- fluid component as the fluid component moves by capillary action, through the spaces transiently formed between the particles.
  • plasma is separated from the cells, such as leukocytes, erythrocytes and platelets, in the blood sample, quickly and efficiently.
  • the particles are latex microsphere or polystyrene beads, such as those sold under the trademark Bang'sTM.
  • the beads are supplied in a liquid suspension.
  • the beads can either be kept moist or dried when used.
  • Other types of particles could be used in the invention, including glass, so long as the particles are effective to separate the fluid components of the sample from the non- fluid components.
  • the spaces between the beads are called “interstitial spaces” or "pores". It is believed that the fluid flows by capillary action from one interstitial space to the next.
  • the microsphere beads act as a fluid filter and as such can be used at any point in an assay where simple fluid filtration, separation or partitioning, is required. Since it is believed that the microspheres act to filter, separate or partition the fluid component from the non-fluid component by capillary action, the microsphere filter may be termed a dynamic capillary filter and this term is used for that purpose herein.
  • the capillary filter is a dynamic filter in the sense that the beads are seen, under a microscope, to move randomly and without an overall direction of movement during the partitioning of the fluid component.
  • capillary channels may be transient.
  • the interstitial spaces between the beads or particles, as well as the contact between the beads, are also expected to show the same transience with respect to movement of the beads or particles during fluid partitioning.
  • the flow of the fluid passing through the interstitial spaces between the beads is likened to flowing along channels formed by the spaces between the beads.
  • the channels are referred to as "capillary" channels because it appears that the fluid flows between the beads by "capillary" action.
  • the size of the space formed between the microspheres is a function of the radius of curvature of the microspheres.
  • the radius of curvature is, for the purposes of the present invention, the same as the diameter of the microsphere.
  • the ratio of the microsphere diameter to pore diameter is approximately 1 to 0.4.
  • this particular embodiment is 10 ⁇ m. This permits an easy fluid flow (and therefore
  • the small spaces formed between the beads provide a certain capillary force when a fluid is present.
  • optimal bead size is 15 ⁇ m, due to the larger size of the bacterial cell. This provides
  • microsphere beads is an effective and inexpensive means for separating plasma from whole blood, as the erythrocytes and leukocytes in the blood will stay on the side of the beads where the sample is applied, while the plasma portion of the blood sample will pass through the beads, by capillary-like action along the interstitial spaces or pores formed between the beads. It is considered that the capillary action observed in the present invention is related to the surface tension exerted by the microspheres on the fluid so as to draw the fluid in a direction away from the beads.
  • the microsphere layer could be impregnated with secondary antibodies or another detection molecule.
  • the microspheres alternately may contain analyte- specific antibodies bound to them, for example, by adsorption or coupling. As the fluid containing the plasma passes through the capillary channels formed by the microspheres the analyte will mobilize the secondary antibodies contained on the microspheres and then react with the primary antibodies contained in the biochip.
  • the microspheres may act solely to separate the cellular component from the fluid component and the microspheres need not be labeled with antibodies.
  • microspheres of the present invention provide an advantage over the prior art technology because it provides improved fluid flow without restriction by the fiber which is present in the chromatographic paper.
  • the microspheres provide a further advantage in that they provide an excellent surface for binding of proteins such as antibodies or other suitable labels.
  • the size of the microsphere beads used to separate the fluid component can be varied based on the viscosity of the sample. Larger beads may be used for more viscous samples for faster fluid flow between the beads.
  • the beads may be of a size up to 5,000 ⁇ m in diameter. Preferably, the beads are of a size up to 50 ⁇ m in
  • the beads are in a range between 5 and 15 ⁇ m in diameter.
  • beads of different colours may be used to facilitate visualization of the beads when they are used as labels and bind to the analyte.
  • the bound beads also serve to increase the density of any bound analyte for subsequent detection by a spectrometer.
  • the regular pattern of the beads also means that light absorption differences could be used for detecting and measuring bound analyte.
  • microsphere beads to quickly separate out a fluid component from a biologic sample can be incorporated into assays for detecting and quantifying analytes present in the sample.
  • this method of separating out a fluid sample from a biologic sample using microsphere beads is incorporated into a one-step assay for analyzing one or more analytes which may be present in the fluid sample.
  • the assay is performed in association with a chamber of defined volume.
  • the chamber is associated with microsphere beads for separating out the fluid sample and detection means for detecting and/or measuring an analyte in the sample.
  • the detection means may be drawn from any of several known methods for detecting an analyte in a sample.
  • the analyte may be recognized using a detection protein, such as an antibody or antigen, which is specific to the analyte.
  • the detection protein may bind to the analyte and itself be detected in any of a number of ways known to those of skill in the art.
  • the detection protein may be an analyte-binding protein that is linked to an enzyme that produces a colored reaction product upon incubation with an appropriate substrate, as is normally done in ELISA-type assays.
  • the detection protein may be bound to another label, which can be detected. Suitable labels include metals such as gold, fluorescent labels, chemical labels, or colorimetric labels.
  • the present invention also pertains to point-of-care diagnostic or prognostic tests, which may include a small chip or cassette for use in assaying biologic samples such as blood.
  • the chip or cassette can be referred to as a biochip, as that termed is broadly defined above.
  • the biochip is created by a pairing together of two carrier surfaces in order to define a specific volume in which a quantitative measurement of analyte(s) present in a sample may be measured.
  • the surfaces in question are a coverslip and a microscope slide but the present invention is not intended to be limited to only these specific embodiments.
  • An important aspect of the present invention is the fact that a fluid sample enters a space of defined volume by capillary action.
  • the defined space is therefore referred to herein as a capillary chamber.
  • the capillary chamber is that volume of space between the bottom of the cover slip and the top of the slide.
  • the amount of fluid which is present between the plates or slides is determined by the volume of space between the slides. Plates of larger surface areas would require greater sample volumes, and, conversely, plates of smaller surface areas require smaller sample volumes.
  • Test systems can be designed which allow for precision testing of very small volumes, in some cases, as small as a few microliters. This facilitates assays of samples having very small volumes, i.e., a droplet of blood from a pinprick.
  • the distance between the two plates is limited only by the ability of the plates to effectively draw a fluid such as plasma between the two plates by capillary action and to retain the fluid in the defined volume.
  • the size of the plates used would also be dictated by practical considerations such as the desired volume for testing.
  • the small sample size required for the present invention also would be useful in medical research that employs experimental animals, such as rodents.
  • experimental animals such as rodents.
  • By employing smaller bodily samples from each individual animal it is possible to take multiple samples from the animal over short periods of time. In this fashion, fewer animals may be needed for each experiment, since in place of multiple animals to follow the results of a particular treatment, multiple samples may be taken from the same animal at different times.
  • In order to quantitatively measure the concentration of an analyte in a sample and to compare test results from one test to another it is advantageous to have a consistent test volume of the fluid sample each time the assay is performed. In this way the analyte measurement is assessed directly without having to adjust for varying volumes.
  • the concentration or quantity of analyte can be assessed directly without difficulty and with consistency from test to test.
  • the chamber of the biochip of the present invention provides that defined volume.
  • the chamber may also have a standardized volume for comparing the results of the assay to those obtained in other assays.
  • the fluid sample is retained by way of surface tension at the ends and edges of the two surfaces.
  • the plates are joined together such that the fluid sample may be readily removed, i.e., at the end opposite the point of fluid entry.
  • the sample may be removed by contacting the sample with a wicking at the end of the chamber opposite the point of fluid entry to withdraw the sample in the chamber.
  • the wick may be a bibulous material or any material capable of withdrawing the sample via capillary action, mass action transfer, or the like. In this fashion, the entire fluid component of the sample may be passed through the chamber.
  • the biochip is of a small size which makes it easily portable.
  • the biochip can be inserted into an analyzer and reaction products between the analyte and detection molecules then can be measured using the analyzer.
  • the biochip may be adapted for use in a vertical orientation if a means is adopted to hold the microspheres in place.
  • a NylonTM mesh or the like may be used to hold the beads, or the beads
  • the carrier surfaces will be referred to as plates; however, the invention is not to be limited only to flat plates. Similarly, all types of surfaces which are able to bind proteins, antigens and other detection molecules are contemplated as being within the scope of the present invention.
  • the composition of the carrier surface of the biochip may include, but is not limited to, glass, plastic and metal. It should be noted that the carrier surface should not be comprised of a material which interferes with analyte detection. In a preferred embodiment, the carrier surface is made of a plastic, such as polystyrene, which can be manufactured at a minimal cost, making it ideal for single-use applications.
  • a drop of a biologic sample such as blood, a blood product, urine, saliva, semen, and the like, is placed on the top surface of the microscope slide and, before entering the capillary chamber, the cellular component of the sample is removed by movement of the fluid component through a group of microsphere beads.
  • a biologic sample such as blood, a blood product, urine, saliva, semen, and the like
  • the cellular component of the sample is removed by movement of the fluid component through a group of microsphere beads.
  • the plasma is separated from the cellular components of blood by movement of the fluid component of the sample through capillary channels in interstitial spaces between the beads.
  • the fluid enters the testing chamber in which the analyte reacts with reagents in the chamber and the reaction product is a measure of the analyte present in the sample.
  • the fluid may be exposed to one or more reagents present on an interior face of a carrier surface.
  • the reagents are exposed in the capillary chamber and available for reacting with one or more analytes which may be present in the fluid sample which ultimately fills the capillary chamber.
  • the reagents are labelled and the quantity of analyte present in a fluid sample is measured based on a reaction product which results from the interaction of the analyte in the sample with the reagent in the chamber.
  • the test results are then compared to standard calibrations to determine the quantity of analyte present in the sample.
  • the reagent is one or more analyte specific antibodies which are adhered to the carrier surface.
  • an antigen is present on an interior face of the carrier surface and the amount of antigen specific antibody in the sample is measured.
  • the protein or other detection molecule When bound to the carrier surface the protein or other detection molecule will project into the defined space where it can react with the analyte in the sample.
  • the detection molecule which is present on the interior face of the carrier surface may be bound to the surface by any one of several means known to a person skilled in the art.
  • Detection molecules are either coated, printed or otherwise bound to one plate or the other using one of several techniques well known in the art. Numerous techniques for immunoassays are known to persons in the art and are described, for example, in “Principles and Practise of Immunology” (1997), C.P. Price and D.J. Newman eds. (Stockton Press) and this document is hereby incorporated by reference into the instant patent application and made a part hereof as if set out in full herein.
  • Analyte-specific antibodies themselves may be labeled with any one of several labels known to persons skilled in the art of such assays.
  • preferred labels include fluorescent labels, colorimetric labels, another microsphere, gold particles or any high contrast molecule. Other labels would be suitable so long as the presence of the label can be detected.
  • microsphere beads having a diameter which is smaller than the test beads can be used so that the smaller beads are mobilized through the larger beads with the movement of the fluid sample (e.g. plasma). The smaller beads can be labeled accordingly.
  • the upper plate for example a coverslip
  • the upper plate has analyte-specific reagents bound on the surface which comes in contact with the fluid.
  • the analyte-specific reagents may be printed on the interior surface of the plate using a protein printer. Suitable protein printing devices are well known in the marketplace. These include ink jet, spray, piezo-electric and bubble jet protein printers. The piezoelectric printer is preferred. Such a printer is available from Biodot (Irvine, CA).
  • the analyte-specific reagent acts as a detection molecule, typically proteins.
  • Preferred surfaces include polystyrene or polypropylene.
  • the use of such printing devices is advantageous in the present invention to allow several different analyte-specific detection molecules to be printed onto the plate or coverslip such that different "lanes" are defined and different analytes may be assessed simultaneously using a single fluid sample. Additional background and calibration lanes can be provided in the same test chamber.
  • the biochip carrier surfaces be colorless or transparent such that a colorimetric, or fluorescent or other reaction products can be read using a suitable spectrometer or other appropriate detection coupled to a reader.
  • the analyte and analyte-specific detection molecule react together there is a change in the intensity of the reaction product in the reaction lane.
  • the change in intensity is measured to determine the amount of analyte present in the sample.
  • a mask may be provided.
  • the mask 32 is made of an opaque material except for the openings 36, 38 and 40 which correspond to lanes 26, 28 and 30 on the plate.
  • the mask is designed to fit neatly over the upper plate 10 so that only the lanes themselves are available to be read.
  • the use of the mask has the advantage of reducing the amount of background noise and setting baseline values when reading the density change in the lanes.
  • the space between the two plates could be divided into lanes and the volume of each lane would similarly be known. This approach would allow multiple tests to be done on a single sample.
  • test results be made available in a short time frame, preferably on the order of 1 to 30 minutes, from beginning to end.
  • An advantage of the present invention is that the fluid sample enters the test chamber in a shorter time than prior art assays, since the use of microsphere beads to separate the plasma from the blood sample eliminates the delay which would occur using fiberglass or chromatographic strips. Cumbersome equipment such as a centrifuge is not required for cell separation.
  • the increased speed and simplicity of the present invention facilitates the test being performed at the point-of-care.
  • the present invention has further advantages over the prior art since the biochip device of the present invention permits several assays to be performed on one sample. This facilitates the speed with which test results can be obtained and minimizes the amount of sample required for testing.
  • the biochip is designed to be read by a portable spectrometer which reads for example, the change in color after the analyte has reacted with the labeled antibody.
  • the spectrometer could also read changes in density, film thickness, mass absorption or diffraction depending on the test reagents used.
  • the spectrometer is a DNAscope (Biomedical Photometries, Inc., Waterloo, Ontario, Canada). Once the analyzer, e.g. the spectrometer, has performed the necessary data calculations the results are transmissible by digital transmission over the telephone lines, by cell phone, or other computer network system.
  • changes occurring during an antibody/analyte reaction may be detected or measured by changes in radio frequency if a radio frequency sensor is incorporated into the biochip detection system.
  • changes in the concentration of a fluorescent reaction product may be detected using a fluorimeter.
  • Data obtained by the methods and devices of the present invention may be accumulated in one or more databases to provide a resource for diagnosis and prognosis.
  • data obtained from a large number of patients afflicted with a disease or condition that is associated with a change in a measurable parameter, i.e., concentration of a metabolite or enzyme in the blood can be pooled and compared to the values obtained for the same parameter in unafflicted patients. Then, a patient suspected to be suffering from the same disease or condition can be diagnosed based on the values obtained for the parameter.
  • the devices and methods of the present invention are advantageous in that they are amenable to point-of-care diagnosis, and further the small sample sizes required for the assays permit multiple and ongoing determinations of the values for the parameters. Therefore, the efficacy of treatment regimens can be followed on a small time scale, so that the delay between treatment and parameter measurement is minimized.
  • a database may be created for each individual patient, based on the numerous measurements taken over a relatively short period of time. In this manner, the progress of the patient can be monitored virtually continuously, and compared to his or her condition at earlier time points to assess improvement or deterioration in the patient's condition.
  • the data obtained for multiple patients can be used to track the initiation and development of disease conditions. Measurements taken of multiple parameters in a large population can be assessed to detect correlations between changes in measurable parameters and the development of a disease. Once such correlations are detected, an individual can be measured for changes in the parameter that are prognostic of the development of the disease.
  • FIG. 1 a preferred embodiment of the biochip of the present application is illustrated in a schematic exploded perspective view.
  • Two carrier plates 10 and 12 are provided.
  • the two plates define a fixed volume therebetween that creates a chamber 14.
  • Lower plate 12 may be longer than upper plate 10 to provide a shelf which acts as an application zone 16 upon which a biologic sample 18 may be applied.
  • a shelf is not essential to the invention but provides a place to allow the sample to be separated by the microsphere beads.
  • microsphere beads 20 which may or may not also include a label zone 22.
  • the microsphere beads 20 may be grouped or bundled using a fluid-permeable material.
  • microsphere beads 20 and label zone 22 are illustrated as separately defined regions; however microsphere beads 20 may also bear the label themselves and in this embodiment the two zones would converge into one with the microsphere beads playing two roles: separation of the fluid and displaying a label to which the fluid is exposed. It is possible that the beads could be placed at the entrance of capillary chamber 14 within the confines of the plates and the sample would be applied to the edge of the biochip where it would enter the chamber by capillary action.
  • microsphere beads 20 may be held in a well 71 having an outlet 72 in fluid communication with chamber 14 on a surface 73.
  • Well 71 holds microsphere beads 20 in place, and outlet 72 has an opening that is smaller than the diameter of microsphere beads 20.
  • Outlet 72 can be fabricated by i.e., use of a laser to have an opening less than the diameter of microsphere beads 20.
  • fluid sample 18 (not shown) is applied to well 71 containing microsphere beads 20, and must first pass through microsphere beads 20 before entering outlet 72. In this manner, none of fluid sample 18 can enter chamber 14 before passing through microsphere beads 20.
  • This embodiment has the advantage of greater sample treatment reliability.
  • outlet 72 may be greater than the diameter of microsphere beads 20 if steps are taken to block passage of microsphere beads 20 through outlet 72 into chamber 14.
  • outlet 72 may be in the shape of one or more holes, and a ball placed in outlet 72 could block passage of microsphere beads 20 through each hole of outlet 72 if the difference in diameter between the ball and outlet 72 is less than the diameter of microsphere beads 20.
  • outlet 72 may be in the shape of a channel, and a rod having a length substantially equal to that of the channel could be used to block passage of microsphere beads 20 through outlet 72, so long as the difference in diameter between the rod and outlet 72 is less than the diameter of microsphere beads 20.
  • the length of the rod is such that none of microsphere beads 20 can pass through the channel to outlet 72 at the ends of the rods.
  • outlet 72 may be of any shape so long as there is a matching element that can be inserted into outlet 72 and block passage of microsphere beads 20 into chamber 14 through outlet 72. More than one size of microsphere beads may be present. In one embodiment, smaller microspheres could nestle in the interstitial spaces formed by the larger beads. The smaller beads could carry secondary labels which would bind to the analyte as it passes through the beads.
  • a sample ID may be affixed to either plate 10 or 12 so long as it does not interfere with the test detection areas on the biochip or with reading the biochip after analyte has reacted with the substance bound to the carrier plate surface.
  • the sample ID is in the form of a barcode.
  • the plates 10 and 12 are preferably colorless and/or transparent.
  • Three detection areas 26, 28, 30 are printed on the inner surface of carrier plate 10: a calibration print zone 26, a detector print zone 28 and a baseline print zone 30.
  • Three detection areas, or zones, are depicted for example only to illustrate how one test biochip may be set up; however, several lanes may be present and the number of lanes dedicated to calibration and/or background can vary depending on what is being tested. The test need not be limited to only three lanes. Several lanes could be defined. In a prefened embodiment of the present invention three lanes are printed on the one plate to permit assessment of background readings as well as calibration of the biochip. It is understood that the background and calibration detection zones need not all be placed on the same biochip. It is advantageous to have the background and calibration readings made on the sample carrier plate in the same assay as the test analyte thereby reducing the variance in test results.
  • a background mask 32 is optionally provided.
  • the mask is designed to cover the outer surface of the carrier plate 10 without blocking the coated or printed detection zones/lanes. Therefore, openings 36, 38 and 40 are, for example, present in the mark to reduce background interference when reading test results.
  • the background mask is made of an opaque material with openings 36, 38 and 40 which correspond to the detection zones 26, 28 and 30 identified on the inner surface of the upper plate.
  • the opening 40 in the mask need not have a corresponding test zone 30 as illustrated so long as the opening 40 is exposed to a part the plate 10 where reagents are not present.
  • Figure 1 illustrates both an antibody/label zone 22 and a microsphere zone 20, both of these zones are optional depending on the type of test one chooses to conduct.
  • fluid sample 18 When fluid sample 18 is applied to application zone 16 it flows through antibody/label zone 22 (if present) and microsphere bead zone 20 (if present) before it reaches edge 34 where the two plates 10 and 12 first meet.
  • edge 34 In the schematic illustration of Figure 1 there is a gap between the zone of microsphere beads and the fluid entry point identified by edge 34.
  • this arrangement of the invention will work, it would be most preferred if the microsphere bead zone 20 and/or label zone abutted against edge 34 of carrier plate 10.
  • Figures 5 and 6 This configuration provides the least distance for the fluid sample to travel and this further minimizes the amount of fluid sample required for testing and is described in greater detail in Example 1.
  • the fluid sample is drawn under edge 34 into chamber 14 which defines a known volume.
  • the fluid sample should be of sufficient volume to pass along application zone 16, through the microsphere and label zone(s) and to completely fill chamber 14.
  • the biochip of the present invention can be scaled to a small size such that a single drop of blood could be a sufficient sample size for testing.
  • Many dimensions are possible to construct based on the principles taught herein. Although dimensions of 1 cm x 3 cm make a device of convenient size, the nature of the testing to be done would dictate the optimum chip size.
  • a shelf portion 16 extends on the bottom plate. On this shelf portion the biologic sample can be applied.
  • the portion of the test which is held, for example the microscope slide may be large but the test assay itself which sits on the slide may be very small.
  • the assay may be miniaturized to accommodate sample fluid volumes as small as about 1 microliter.
  • Figure 2 is a sectional view taken along lines 2 - 2 illustrating the same elements as referenced in Figure 1.
  • Figure 2 A is an end elevation view of Figure 2 along lines 2 A - 2 A illustrating that the end of the device may be open, to allow the fluid to be removed from the chamber.
  • a suitable wicking material would be applied to the open end and the fluid would be drawn through thereby allowing additional fluid to enter the chamber. This could be either a continuous or a discontinuous process.
  • FIG. 1 Illustrated in all of Figures 1, 2 and 2 A is a spot of glue 58 which is one way to hold plates 10 and 12 together.
  • the glue 58 also illustrated in Figure 6, another embodiment of the invention.
  • Other methods to hold plates 10 and 12 together would be obvious to one of skill in the art.
  • plates 10 and 12 could be fabricated such that they snap together, and are held in place by frictional forces.
  • FIGs 7 and 7 A are illustrations of another use of the microsphere method of separation in a one-step assay.
  • the microspheres are used in conjunction with chromatography paper.
  • the biologic sample 18 is placed on a surface such as a microscope slide 52'. It may be placed directly on the microsphere beads 50 (as illustrated) or beside them.
  • the fluid component of the sample then flows through the beads 50 separating from a non- fluid component present in the sample 18.
  • the beads abut against or sit close to a fiberglass filter pad 60 which abuts with a label pad 62.
  • the label pad 62 is usually a fiberglass pad impregnated with the label of interest for labeling analyte in the fluid sample.
  • the fluid flows through the filter 60 and label pad 62.
  • any analyte present in the fluid will be labeled as it flows through the label pad.
  • the fluid then flows into the nitrocellulose chromatography strip 64 where the test results are read, usually as a color change or band on the nitrocellulose strip.
  • the fiberglass filter 62 may be eliminated entirely (not illustrated).
  • the fiberglass label pad 62 may be replaced by microsphere beads 66.
  • the beads 66 are acting as a source of label, not as a filter and the fiberglass filter 60' serves as a spacer between the two sets of beads 50 and 66, respectively.
  • the microspheres 66 can be used to label an analyte present in the fluid directly, without requiring the microsphere filter 50 or the fiberglass spacer 60'.
  • FIG. 7 and 7 A are illustrative of how cunent assay methodologies may be modified using the microsphere bead technology of the present invention as taught herein.
  • the biochip may also include a cap 75, shown in Fig. 21 in an inverted format, that is adapted to slide back and forth in a lengthwise direction on lower plate 12.
  • Cap 75 snaps onto lower plate 12 and is slidably held in place on lower plate 12 by tabs 76 which run in tracks 74 of lower plate 12 (Fig. 20B).
  • Cap 75 covers well 71 and protects beads 20 (not shown) after they are added to well 71. This protects beads 20 during transportation and storage of the biochip.
  • cap 75 is pushed in a direction toward chamber 14, exposing beads 20 for application of sample 18.
  • Lower plate 12 may optionally contain stops (not shown) to halt the motion of cap 75 along tracks 74, or tracks 74 may be of a defined length.
  • the assay device and techniques of the present invention are very useful in that they can be used for small volumes of many kinds of fluid samples.
  • the description refers specifically to proteins, any number of other markers would be suitable so long as a labeling system can be devised for the detection and measurement of the marker in the system.
  • the present invention could be used to measure and/or detect the presence of microorganisms such as bacteria, viruses, fungi or other infectious organisms.
  • the biochip device of the present invention can be calibrated for the type of assay and the type of analyte so that a table of standard values may be constructed.
  • the assay system or the present invention can detect the levels of a particular hormone or the amount of a drug in a patient's system and this standardized data can be used to make diagnostic and/or prognostic determinations for a given individual.
  • the ease of use and simplicity of the device of the present invention coupled with the minimal sample size needed for each reading, means that many multiple tests can be performed on the same patient over a relatively brief period of time.
  • the methods of the present invention facilitate sampling far more frequently. As a result, much more data can be obtained for each patient, and the changes over time of a particular analyte can be more precisely followed.
  • measurements can be taken earlier in time, including measurements that can serve as baseline values.
  • the above-identified method can be used to prepare a prognostic test, based on data accumulated from a large number of users. Over time, the changes in a parameter associated with development of a disease can be followed to determine at what point the disease manifests, in a large number of patients. This information can be used to create a predictive database, wherein the course of the disease may be predicted as a function of the change in the parameter in an individual patient.
  • Tables of standard values can be constructed, based on the known values of the parameters in the target patient group. Once the table of standard values is constructed, data is collected from a patient on a regular basis and patient-specific databases constructed based on the patient's medical history, current health and the test results. Optionally, the data can be transmitted by digital transmission systems over a computer network via modem, the internet, cellular phone systems, cable lines, telephone lines, fiberoptic lines, satellite systems or other similar technology. These databases can be used in the development of neural network algorithms, for assessment of current patient test results and diagnoses as well as for predicting certain health outcomes for a given individual.
  • a neural network algorithm is found in Example 3 below and a sample Receiver Operator Curve (ROC) is illustrated in Figure 8.
  • the development of the algorithms for the applied neural network will be a function of the medical condition being assessed. Large amounts of patient data will first have to be accumulated in order to have reliable predictive outcomes.
  • the neural network can be trained to recognize the concentration of analyte which is diagnostic or prognostic, using the standardized assays of the present invention.
  • the data and algorithms are encoded in an electronic chip which is placed in the reader, for example a spectrometer, such that the printout from the reader will also identify a particular diagnosis or prognosis simultaneously with providing the test result.
  • the diagnostic or prognostic test result will be optimized as the number of data points increases. With more patient data the predictive and/or diagnostic result will be made with greater certainty.
  • the biochip may have a radiofrequency sensor incorporated into carrier plate 10.
  • a radiofrequency sensor incorporated into carrier plate 10.
  • more than one test can be run simultaneously on the same biochip and therefore the certainty of the diagnosis or prognosis can be improved. As the number of markers increases so does the certainty of measurement.
  • One of the many examples of uses of the biochip/cassette of the present invention is to measure blood proteins indicating peripheral vascular disease using a drop of the patient's blood.
  • the present invention is also applicable to small particles other than the microsphere beads described herein.
  • the separation technology of the present invention also works using non-uniform particles including silica-based particles, for example sand grains, even though these particles are not necessarily spherical in shape nor uniform in size, as shown in Example 7 below.
  • Non-uniformity of the particles makes the separation less efficient because it is somewhat slower but effective separation is still achieved, at least for qualitative assays.
  • Example 7 using sand grains, the separation does not appear to happen as efficiently since fewer organisms are separated from the sample in the same time period as the separation using microsphere beads as described in Examples 4, 5 and 6. Still, the organisms are successfully separated and can be further tested or assayed accordingly.
  • the use of silica and other similar particles is advantageous over the microsphere beads because they are less expensive and may be more readily available in less developed and developing countries.
  • the microsphere beads of the present invention can be generalized to a phenomenon of particles in general and the invention is not restricted to spherical beads.
  • Another advantage of the use of silica-type particles is that silica is known in the art to selectively bind proteins and nucleic acids. Silica-based separation particles could be used to devise certain protein and/or nucleic acid positioning mechanisms.
  • the assays and devices of the present invention can be particularly helpful in identifying the presence of harmful and pathogenic bacteria in certain biologic samples, such as E. coli strain O157:H7, salmonella, listeria, clamydia and other bacteria and microorganisms such as viruses.
  • the assays of the present invention could be used to test food samples for certain pathogens. They could also be used in human or veterinary medicine for diagnosis of infectious diseases.
  • Example 1 Verification of Plasma Flow and Separation from Whole Human Blood
  • the capillary chamber defines a known space, the volume of which can be calculated and predetermined. This demonstrated that the microsphere beads are able to readily and effectively separate plasma from whole blood and to pass, via the capillary channels formed between the microsphere beads, into the capillary chamber.
  • this example (schematically illustrated in Figure 7) demonstrated the use of microsphere separation of plasma from a blood sample of human whole blood.
  • the plasma was separated using latex microsphere beads (Bang'sTM) 50 and then drawn into a standard nitrocellulose chromatography strip.
  • the fiberglass pads which are usually used to retain red blood cells in the
  • Fiberglass pad 60 effectively functions as a spacer between the beads 50 and label pad 64 although it could also be used as a second filter. Fiberglass filter 60 may be eliminated entirely and microsphere beads 50 abut directly with label pad 64 (not illustrated).
  • FIG. 7A Illustrated in Figure 7A is another embodiment where, instead of a fiberglass label pad 62, microsphere beads 66 are used as the label region of the test device. A fiberglass filter pad 60' is used as a spacer between the two sets of beads, 50 and 66.
  • T would be 1 for a coagulation result, and 0 for a non- coagulation result.
  • TST(C,b,T) be the test result for a testing vector a, given cutoff C, and target output T.
  • a neural network has 3 layers; the first INPUT layer, the second HIDDEN layer, and the third OUTPUT layer:
  • the neurons are connected by a set of weights ⁇ w(i,j,k) ⁇ .
  • w( 1,2,4) connects the second neuron of the first layer with the fourth neuron of the second layer.
  • the activation is defined recursively as follows:
  • a(i ) ⁇ ⁇ 1/ (1 + exp (- sum(k) ⁇ w(i- l,k,j)a(i- l,k) ⁇ ))
  • the weights are adjusted to minimize ERMS, while maintaining good performance on new data.
  • Figure 11 shows a fewer number of bacteria per field but is
  • Example 5 Separation of E. coli from a Bread Suspension
  • Escheria coli E. coli was successfully separated from a bread suspension using the methodology and apparatus of the present invention.
  • a bread and NaCl mixture was prepared. 200 mg of bread was weighed.
  • a bread suspension was prepared by repeatedly mixing 500 ⁇ l 150 mM NaCl with the
  • E. coli strain: DH5 ⁇ was added in a 100 ⁇ l aliquot to the bread suspension.
  • the suspension was mixed again to create an E. coli/bread suspension. 100 ⁇ l of the
  • E. colifb ⁇ ead suspension was placed on the biochip and almost instantaneously the microsphere beads acted to partition a fluid component containing bacteria from the sample but none of the solid particles from the suspension.
  • Figure 12 shows a typical field of view of the unseparated E. co/t/bread suspension.
  • Figure 13 shows the clean separation of bacteria in the fluid portion isolated using microsphere beads having a
  • microsphere beads partitioned out a fluid component containing bacteria.
  • the separated bacteria can now be stained to further identify
  • the red blood cells flowed through the filtration particles. A uniform blood smear was obtained.
  • Food samples (25 gm or 25 ml) spiked with various amounts of E. coli strain O157:H7 were enriched for bacterial growth in various media for 18 hours at 37 °C with shaking at 150 RPM.
  • the media tested were: BPW-VC (buffered peptone water with vancomycin and cefsulodin); mEC broth (Merck); mTSB (trypticase soy broth containing novobiocin, Merck); and CASO broth (Merck).
  • Food samples investigated were raw milk, ground beef, cheese spread, and soft cheese (Camambert). A portion of the enriched sample was then stained with Alexa 594-labeled anti-0157 antibody.
  • the stained sample was then passed into a biochip without microsphere beads and stained bacteria visualized using a DNAscope.
  • the biochip assay was compared to a conventional lateral flow assay. It was found that the media used to enrich the had an influence on the sensitivity of the procedure. However, in general, the biochip assay was more sensitive than the conventional lateral flow assays. In general, using a conventional
  • Biochip assay depending on the E. coli O157:H7 strain. Thus, the biochip assay was between about 100-1,000 times more sensitive than the lateral flow assay.
  • Raw milk E. coli O157:H7 strain ATCC#700531 was spiked into raw milk (70 cfu (colony- forming units) of bacteria), and the resulting mixture grown in various culture media.
  • the biochip assay was able to detect bacteria when the raw milk sample was enriched in CASO broth and BPW-VC, and a weakly positive result was obtained when the raw milk sample was enriched in mEC media. However, no bacteria were detectable when the raw milk sample was grown in mTSB media. Similar results were obtained in a conventional lateral flow test, except that no bacteria were detected in a raw milk sample enriched in mEC media.
  • E. coli O157:H7 strain ATCC#700531 was spiked into ground beef sample grown in BPW-VC, CASO broth or mEC media.
  • the conventional lateral flow assay it was found that that the lower limit of detection of the culture enriched in BPW-VC or CASO broth was 3 cfu added to the sample, and the bacteria were not detected in the sample enriched in mEC media.
  • the lower limit of detection in the BPW-VC medium was a nominal 0.3 cfu added to the sample.
  • Soft cheese (CamambertL E. coli O157:H7 strain ATCC#35150 was spiked into ground beef samples grown in BPW-VC, CASO broth or mEC media. The samples were spiked with 0, 0.2, 2, or 20 cfu bacteria. The bacteria grew well in mEC culture, but not in CASO broth. Using the lateral flow test, bacteria were detected in the BPW-VC cultures at 2 cfu and 20 cfu, and in mEC cultures at 20 cfu. Similar results were obtained using the biochip assay. However, some food samples that have a high fat content, such as milk and cheese, contain auto fluorescent materials that interfere with detection by immunofluorescent staining.
  • Ground chicken E. coli O157:H7 strain ATCC#35150 was spiked into ground chicken samples grown in BPW-VC, CASO broth or mEC media. While there were significant levels of background bacterial growth, the biochip assay was able to detect 1 cfu bacteria in a BPW-CV-enriched sample, which was negative by the lateral flow assay.
  • Example 9 Detection Limit of E. coli O157 in Pure Culture and Ground Beef with or without Microsphere Beads
  • the experiment was designed to compare the detection limits of E. coli 0157 in pure bacterial culture, with or without treatment using microsphere beads.
  • a pure culture of bacteria was ten- fold serially diluted using CASO broth between 10 "1 and 10 "7 .
  • the samples diluted to 10 "3 , 10 "4 , 10 "5 , 10 "6 and 10 "7 were stained with Alexa Fluor 594-labeled anti-E. coli 0157 antibody (diluted 1:25).
  • Fluid samples may be concentrated by contacting the sample with a superabsorbent polymer, such as those containing acrylamide and/or dextran, which are capable of absorbing large amounts of water and/or small ionic species.
  • a superabsorbent polymer such as those containing acrylamide and/or dextran, which are capable of absorbing large amounts of water and/or small ionic species.
  • the superabsorbent polymer is a non-ionic polymer.
  • the superabsorbent polymer may be held in a syringe or other suitable container, and the sample mixed with the polymer while in the syringe.
  • the polymer gel in the syringe may also include another molecule to be exposed to the sample during the concentration step, such as, for example, a labeled monoclonal antibody.
  • the concentrated sample may then be expressed from the syringe for further treatment.
  • the concentrated sample may be treated as described above to separate a non-fluid component from a fluid component for further testing.
  • the gel was incubated with solutions containing polystyrene beads (0.01%, w/v) ranging in
  • the gel concentrated the beads by a
  • the gel concentrated the beads by a factor of 4.3.
  • the gel concentrated the beads by a factor of 4.3.

Abstract

Cette invention se rapporte à un dispositif permettant de séparer un fluide d'un échantillon biologique, lorsque cet échantillon contient un composant fluide et un composant non fluide. Cette invention concerne également un procédé de séparation d'un fluide d'un échantillon biologique, qui consiste à mettre l'échantillon fluide en contact fluide avec les microsphères, pour que le composant fluide se déplace par capillarité entre les microsphères le long des canaux capillaires qui se sont formés par voie transitoire dans les espaces compris entre les microsphères et laissant le composant non fluide derrière eux. Dans les procédés de cette invention, la phase consistant à séparer le fluide peut être combinée avec d'autres techniques de dosage destinées à détecter et/ou à mesurer un ou plusieurs analytes pouvant être présents dans l'échantillon fluide, telles que des techniques d'immunodosage et d'analyse chromatographique. Ces procédés peuvent en outre être combinés avec des groupes de microsphères à utiliser dans la phase de détection de l'analyte, ainsi que dans l'étape de séparation, les microsphères agissant alors comme marqueurs pour l'analyte ou comme source de marqueur pour l'analyte.
PCT/US2000/013056 1999-06-18 2000-05-12 Dispositif et procede d'analyse d'un echantillon biologique WO2000078917A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU47126/00A AU4712600A (en) 1999-06-18 2000-05-12 Device and method for analyzing a biologic sample
US09/866,305 US20020019062A1 (en) 1999-06-18 2001-05-25 Assay devices
US11/319,117 US20060105469A1 (en) 1999-06-18 2005-12-27 Assay devices

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/335,732 US6403384B1 (en) 1998-11-16 1999-06-18 Device and method for analyzing a biologic sample
US09/335,732 1999-06-18
CAPCT/CA99/01079 1999-11-12
PCT/CA1999/001079 WO2000029847A2 (fr) 1998-11-16 1999-11-12 Dispositif et procede d'analyse d'un echantillon biologique

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/335,732 Continuation-In-Part US6403384B1 (en) 1998-11-16 1999-06-18 Device and method for analyzing a biologic sample

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/866,305 Continuation-In-Part US20020019062A1 (en) 1999-06-18 2001-05-25 Assay devices

Publications (1)

Publication Number Publication Date
WO2000078917A1 true WO2000078917A1 (fr) 2000-12-28

Family

ID=25683177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013056 WO2000078917A1 (fr) 1999-06-18 2000-05-12 Dispositif et procede d'analyse d'un echantillon biologique

Country Status (2)

Country Link
AU (1) AU4712600A (fr)
WO (1) WO2000078917A1 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004061454A1 (fr) * 2002-12-19 2004-07-22 Kimberly-Clark Worldwide, Inc. Reduction de l'effet crochet dans des dispositifs d'essais comprenant une membrane
WO2007104962A1 (fr) * 2006-03-11 2007-09-20 The Central Science Laboratory (Csl) Representing The Secretary Of State For Environment, Food And Rural Affairs Procédé et kits de purification
US7645373B2 (en) 2003-06-20 2010-01-12 Roche Diagnostic Operations, Inc. System and method for coding information on a biosensor test strip
US7645421B2 (en) 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US7651841B2 (en) 2001-12-24 2010-01-26 Kimberly-Clark Worldwide, Inc. Polyelectrolytic internal calibration system of a flow-through assay
US7670786B2 (en) 2002-08-27 2010-03-02 Kimberly-Clark Worldwide, Inc. Membrane-based assay devices
US7682817B2 (en) 2004-12-23 2010-03-23 Kimberly-Clark Worldwide, Inc. Microfluidic assay devices
US7713748B2 (en) 2003-11-21 2010-05-11 Kimberly-Clark Worldwide, Inc. Method of reducing the sensitivity of assay devices
US7718439B2 (en) 2003-06-20 2010-05-18 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US7781172B2 (en) 2003-11-21 2010-08-24 Kimberly-Clark Worldwide, Inc. Method for extending the dynamic detection range of assay devices
US7790471B2 (en) 2005-12-13 2010-09-07 Kimberly-Clark Worldwide, Inc. Metering technique for lateral flow assay devices
US7803319B2 (en) 2005-04-29 2010-09-28 Kimberly-Clark Worldwide, Inc. Metering technique for lateral flow assay devices
US7829328B2 (en) 2003-04-03 2010-11-09 Kimberly-Clark Worldwide, Inc. Assay devices that utilize hollow particles
US7838258B2 (en) 2005-12-14 2010-11-23 Kimberly-Clark Worldwide, Inc. Meter strip and method for lateral flow assay devices
US7851209B2 (en) 2003-04-03 2010-12-14 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in assay devices
US7858384B2 (en) 2005-04-29 2010-12-28 Kimberly-Clark Worldwide, Inc. Flow control technique for assay devices
US7943395B2 (en) 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US7943089B2 (en) 2003-12-19 2011-05-17 Kimberly-Clark Worldwide, Inc. Laminated assay devices
US7964340B2 (en) 2004-06-30 2011-06-21 Kimberly-Clark Worldwide, Inc. One-step enzymatic and amine detection technique
US8058077B2 (en) 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
US8206565B2 (en) 2003-06-20 2012-06-26 Roche Diagnostics Operation, Inc. System and method for coding information on a biosensor test strip
US8298828B2 (en) 2003-06-20 2012-10-30 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US8367013B2 (en) 2001-12-24 2013-02-05 Kimberly-Clark Worldwide, Inc. Reading device, method, and system for conducting lateral flow assays
US8535617B2 (en) 2007-11-30 2013-09-17 Kimberly-Clark Worldwide, Inc. Blood cell barrier for a lateral flow device
WO2014209849A1 (fr) * 2013-06-24 2014-12-31 Idexx Laboratories, Inc. Surveillance de colonies d'animaux au moyen d'échantillons de matière fécale
CN104583752A (zh) * 2012-07-13 2015-04-29 生物梅里埃公司 溶解存在于样品中的微生物、提取并提纯所述微生物的核酸以用于分析目的的自动化系统
AU2012231737B2 (en) * 2011-03-24 2015-07-23 Ningkasai Technology (Shanghai) Co, Ltd. Micro-devices for disease detection
US9410915B2 (en) 2004-06-18 2016-08-09 Roche Operations Ltd. System and method for quality assurance of a biosensor test strip
CN111693413A (zh) * 2020-04-23 2020-09-22 杭州兴浩晖生物科技有限公司 变量光栅微信号分离装置及其制造方法
CN112649337A (zh) * 2020-12-21 2021-04-13 张家口市杰星电子科技有限公司 一种油烟在线监控方法及装置

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821066A (en) * 1994-05-18 1998-10-13 The Research & Development Institute, Inc. Simple, rapid method for the detection, identification and enumeration of specific viable microorganisms
US5869345A (en) * 1991-05-29 1999-02-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing conductive barrier
US5912116A (en) * 1988-03-14 1999-06-15 Nextec Applications, Inc. Methods of measuring analytes with barrier webs
US6046058A (en) * 1998-11-20 2000-04-04 Sun; Ming Color-coded test strip

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912116A (en) * 1988-03-14 1999-06-15 Nextec Applications, Inc. Methods of measuring analytes with barrier webs
US5869345A (en) * 1991-05-29 1999-02-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing conductive barrier
US5821066A (en) * 1994-05-18 1998-10-13 The Research & Development Institute, Inc. Simple, rapid method for the detection, identification and enumeration of specific viable microorganisms
US6046058A (en) * 1998-11-20 2000-04-04 Sun; Ming Color-coded test strip

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367013B2 (en) 2001-12-24 2013-02-05 Kimberly-Clark Worldwide, Inc. Reading device, method, and system for conducting lateral flow assays
US7651841B2 (en) 2001-12-24 2010-01-26 Kimberly-Clark Worldwide, Inc. Polyelectrolytic internal calibration system of a flow-through assay
US7670786B2 (en) 2002-08-27 2010-03-02 Kimberly-Clark Worldwide, Inc. Membrane-based assay devices
WO2004061454A1 (fr) * 2002-12-19 2004-07-22 Kimberly-Clark Worldwide, Inc. Reduction de l'effet crochet dans des dispositifs d'essais comprenant une membrane
US7662643B2 (en) 2002-12-19 2010-02-16 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in membrane-based assay devices
US8034397B2 (en) 2003-04-03 2011-10-11 Kimberly-Clark Worldwide, Inc. Methods of making assay devices utilizing hollow particles
US7829328B2 (en) 2003-04-03 2010-11-09 Kimberly-Clark Worldwide, Inc. Assay devices that utilize hollow particles
US7851209B2 (en) 2003-04-03 2010-12-14 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in assay devices
US7645421B2 (en) 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US7645373B2 (en) 2003-06-20 2010-01-12 Roche Diagnostic Operations, Inc. System and method for coding information on a biosensor test strip
US7718439B2 (en) 2003-06-20 2010-05-18 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8298828B2 (en) 2003-06-20 2012-10-30 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US8206565B2 (en) 2003-06-20 2012-06-26 Roche Diagnostics Operation, Inc. System and method for coding information on a biosensor test strip
US8058077B2 (en) 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
US8507289B1 (en) 2003-06-20 2013-08-13 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8586373B2 (en) 2003-06-20 2013-11-19 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US7713748B2 (en) 2003-11-21 2010-05-11 Kimberly-Clark Worldwide, Inc. Method of reducing the sensitivity of assay devices
US7943395B2 (en) 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US7781172B2 (en) 2003-11-21 2010-08-24 Kimberly-Clark Worldwide, Inc. Method for extending the dynamic detection range of assay devices
US7943089B2 (en) 2003-12-19 2011-05-17 Kimberly-Clark Worldwide, Inc. Laminated assay devices
US9410915B2 (en) 2004-06-18 2016-08-09 Roche Operations Ltd. System and method for quality assurance of a biosensor test strip
US7964340B2 (en) 2004-06-30 2011-06-21 Kimberly-Clark Worldwide, Inc. One-step enzymatic and amine detection technique
US7682817B2 (en) 2004-12-23 2010-03-23 Kimberly-Clark Worldwide, Inc. Microfluidic assay devices
US7858384B2 (en) 2005-04-29 2010-12-28 Kimberly-Clark Worldwide, Inc. Flow control technique for assay devices
US7803319B2 (en) 2005-04-29 2010-09-28 Kimberly-Clark Worldwide, Inc. Metering technique for lateral flow assay devices
US8124421B2 (en) 2005-04-29 2012-02-28 Kimberly-Clark Worldwide, Inc. Flow control technique for assay devices
US7790471B2 (en) 2005-12-13 2010-09-07 Kimberly-Clark Worldwide, Inc. Metering technique for lateral flow assay devices
US7838258B2 (en) 2005-12-14 2010-11-23 Kimberly-Clark Worldwide, Inc. Meter strip and method for lateral flow assay devices
US8043811B2 (en) 2006-03-11 2011-10-25 The Food & Environment Research Agency (FERA) representing the Secretary of State for Environment, Food and Rural Affairs Purification method and kits
WO2007104962A1 (fr) * 2006-03-11 2007-09-20 The Central Science Laboratory (Csl) Representing The Secretary Of State For Environment, Food And Rural Affairs Procédé et kits de purification
GB2449045A (en) * 2006-03-11 2008-11-05 Central Science Lab Representing Purification method and kits
US8535617B2 (en) 2007-11-30 2013-09-17 Kimberly-Clark Worldwide, Inc. Blood cell barrier for a lateral flow device
AU2012231737B2 (en) * 2011-03-24 2015-07-23 Ningkasai Technology (Shanghai) Co, Ltd. Micro-devices for disease detection
CN104583752A (zh) * 2012-07-13 2015-04-29 生物梅里埃公司 溶解存在于样品中的微生物、提取并提纯所述微生物的核酸以用于分析目的的自动化系统
WO2014209849A1 (fr) * 2013-06-24 2014-12-31 Idexx Laboratories, Inc. Surveillance de colonies d'animaux au moyen d'échantillons de matière fécale
CN111693413A (zh) * 2020-04-23 2020-09-22 杭州兴浩晖生物科技有限公司 变量光栅微信号分离装置及其制造方法
CN112649337A (zh) * 2020-12-21 2021-04-13 张家口市杰星电子科技有限公司 一种油烟在线监控方法及装置

Also Published As

Publication number Publication date
AU4712600A (en) 2001-01-09

Similar Documents

Publication Publication Date Title
WO2000078917A1 (fr) Dispositif et procede d'analyse d'un echantillon biologique
US6403384B1 (en) Device and method for analyzing a biologic sample
JP4544498B2 (ja) 生物学的サンプルの分析装置および方法
EP1891447B1 (fr) Procédés et dispositifs de détermination par écoulement latéral en deux étapes
DK1824991T3 (en) Device and method for the detection of analytes
US20060105469A1 (en) Assay devices
US20100284857A1 (en) Portable Diagnostic Device and Method for Determining Temporal Variations in Concentrations
KR101096924B1 (ko) 단방향 유동 검정장치
US20110124130A1 (en) Device and method for analysis of samples with depletion of analyte content
US7244393B2 (en) Diagnostic device and system
US20020076804A1 (en) Affinity binding-based system for detecting particulates in a fluid
US20100015634A1 (en) In situ lysis of cells in lateral flow immunoassays
CN211148665U (zh) 一种用于检测流体样本中目标分析物的侧向流动测定设备
JPH08507210A (ja) 診断アッセイにおける使い捨て装置
US20130236914A1 (en) Devices and methods for analysis of samples with depletion of analyte content
US5250412A (en) Swab device and method for collecting and analyzing a sample
JP2008537145A (ja) 半定量的免疫クロマトグラフ装置
JP2006511810A (ja) 被検物をマイクロ流体デバイスの多チャネルに分割する方法及び装置
WO2010009206A2 (fr) Lyse in situ de cellules dans des analyses immunologiques à écoulement latéral
EP1879028B1 (fr) Utilisation d'albumine, P-aminophényl N-acétyl ß-D glucosaminide bovine en tant que contrôle positif pour dispositif de dosage immunologique
WO2008156491A2 (fr) Dispositifs et procédés pour l'analyse d'échantillons avec épuisement de la teneur en analyte
US8664001B2 (en) Immunochemical filter device and methods for use thereof
WO2001024931A1 (fr) Dispositif capillaire de separation de composants non desires d'un echantillon liquide et procede relatif
EP1782067A1 (fr) Dispositif de filtre, procede, kit et utilisation de celui-ci
CA2289416C (fr) Dispositif et methode pour l'analyse d'un echantillon biologique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09866305

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP